Introduction
Infection by human herpes virus 8 (HHV-8), previously called Kaposi's sarcoma herpes virus (KSHV), is associated with the development of Kaposi's sarcoma (Chang et al., 1994; Moore et al., 1996) , an angiogenic neoplasm mainly composed of endothelial cells, as well as with the development of two B-cell lymphoproliferative disorders: primary effusion lymphoma (PEL) (Cesarman et al., 1995; Arvanitakis et al., 1996; Nador et al., 1996) and multicentric Castleman's disease (Soulier et al., 1995) . Like other herpesviruses, HHV-8 preferentially establishes a latent infection in target cells but can be induced to undergo lytic replication by treatment with chemical agents such as the phorbol ester tetradecanoyl phorbol acetate (TPA) or sodium butyrate (Miller et al., 1997; Yu et al., 1999) and by inflammatory cytokines, particularly IFNg (Monini et al., 1999) .
Unlike other human tumor viruses that have evolved multifunctional viral oncogenes that control viral replication and oncogenesis (for a review see reference Sarid et al., 1999) , HHV-8 has developed unique mechanisms for altering cellular proliferative and apoptotic control pathways by incorporating viral homologues to several cell regulatory genes into its genome. These HHV-8-encoded cellular homologues include: cytokine and signal transduction intermediates , a cell-cycle regulator (v-cyclin D, encoded by open-reading frame (ORF) 72) and inhibitors of apoptosis , v-IL-6) (Gwack et al., 2001; Montaner et al., 2001; Means et al., 2002) . Among the vIRFs, vIRF-1 (ORF K9) has been shown to disrupt the formation of transcriptionally active IRF-3-CBP/p300 complexes, thus blocking the early steps of the IFN response (Lin et al., 2001) . Recently, lymphoma cells infected with HHV-8 were shown to be autocrine dependent on vIL-6 (ORF K2) for growth but not cellular IL-6 (Chatterjee et al., 2002) .
Targeting the activation of the IKK-NF-kB signaling pathway represents an ideal strategy during the early stages of virus infection and replication: activation of the NF-kB pathway is an immediately early event, does not require de novo protein synthesis and results in a strong transcriptional stimulation of viral as well as cellular genes (for a review see reference Hiscott et al., 2001) . Most NF-kB-activating stimuli such as viral and bacterial pathogens, cytokines and stress-inducing agents (Pahl, 1999) converge on and stimulate the IkB kinase (IKK) complex (for a review see reference Karin and Ben-Neriah, 2000) . The IKK complex is composed of three subunits: the IKKa and IKKb kinase subunits (Rothwarf et al., 1998) and the regulatory IKKg subunit Sun et al., 2000) . NF-kB dimers are predominantly confined to the cytoplasm in unstimulated cells in association with the IkB inhibitory proteins; however, when IKK is activated (DiDonato et al., 1997) , the IkB inhibitor is phosphorylated, leading to its polyubiquitination and subsequent proteasomemediated degradation (DiDonato et al., 1996) . These events promote nuclear translocation of NF-kB, DNA binding and activation of gene promoters containing the consensus sequence 5 0 -GGGRNNYYCC-3 0 (for a review see reference Hiscott et al., 2001) . Despite the fact that IKKa and IKKb show the same substrate specificity in vitro , in vivo-only IKKb is essential for IkB phosphorylation and degradation Hu et al., 1999) .
NF-kB has been shown to be constitutively active in HHV-8-infected PEL cells (Keller et al., 2000) , mediated in part through the expression of the latent vFLIP (ORF K13) that binds to and persistently activates the IKK complex (Liu et al., 2002) . Overexpression of the viral G-protein-coupled receptor (vGPCR, ORF 74) has also been shown to induce NF-kB (Montaner et al., 2001; Pati et al., 2001; Schwarz and Murphy, 2001; Chiou et al., 2002; Smit et al., 2002) through the activation of the PI3K/AKT and IKK pathways (Montaner et al., 2001; Pati et al., 2001) . vGPCR has been detected in HHV-8-infected PEL cells undergoing lytic replication, consistent with its classification as an early lytic gene product (Sun et al., 1999; Chiou et al., 2002) .
The aim of the present study was to investigate the potential role for NF-kB activity in HHV-8 lytic replication in PEL cells. We demonstrate that induction of HHV-8 replication induces NF-kB DNA-binding activity through the IKK kinase complex and subsequent phosphorylation and degradation of IkBa. NF-kB activation is essential for the ability of HHV-8 virions derived from PEL cells to initiate a de novo infection of human endothelial Ea.hy926 cells. Taken together, these studies demonstrate that NF-kB activation is a key component of HHV-8 replication, possibly required to induce the expression of viral and/or cellular genes essential for HHV-8 infectivity.
Results

Induction of NF-kB during the HHV-8 lytic cycle
To investigate NF-kB activation during the transition of HHV-8 from latent to lytic replication, the PEL cell line body cavity-based lymphoma (BCBL)-1 was stimulated with TPA, a phorbol ester known to induce the HHV-8 lytic cycle. Whole-cell extracts were collected at various times after induction and analysed by electrophoretic mobility shift assay (EMSA) for NF-kB binding to the PRDII element of the IFN-b gene. Treatment of PEL cells with TPA induced transient activation of NF-kB after 1 h ( Figure 1a , lane 2); however, a second peak of NF-kB DNA-binding activity was observed at 65 h postinduction exclusively in BCBL-1 cells (Figure 1a , lane 6) but not in control cells (not shown). To demonstrate that the secondary wave of NF-kB activity correlated with the induction of HHV-8 lytic replication, TPA stimulation was performed in the presence of methotrexate (MTX), which interferes with the tran- Figure 1 Late NF-kB activation in BCBL-1 cells correlates with HHV-8 lytic replication. (a) Kinetics of NF-kB activation in BCBL-1 cells following TPA (20 ng/ml) treatment were analysed by EMSA. Nuclear extracts (5 mg) from BCBL-1 cells treated with TPA or with a combination of TPA and 1 mM MTX (an inhibitor of lytic protein production) for various time points were analysed for NF-kB binding to the PRDII probe. The positions of the NF-kB complex as well as a nonspecific band and free probe are indicated. (b) Nuclear extract from BCBL-1 cells after 65 h of TPA stimulation was further analysed by EMSA supershift with specific antibodies against the NF-kB subunits p50, p65, c-Rel, RelB and p52, as indicated. (c) Nuclear extracts (50 mg) from (a) were analysed for lytic protein production by immunoblotting using an antibody against the product of ORF-26 (minor capsid protein). A blot against TFIID was used as a control for equal protein loading NF-jB activity and HHV-8 infectivity M Sgarbanti et al scription of lytic but not latent genes (Curreli et al., 2002) . Under these conditions, NF-kB binding was observed in BCBL-1 cells at 1 h post-TPA ( Figure 1a 
IKK induction during HHV-8 lytic reactivation
To determine if the NF-kB DNA-binding activity during induction of the HHV-8 lytic cycle correlated with an increase in IKK kinase activity, an in vitro IKK kinase assay was performed. The HHV-8-positive PEL cell line BCBL-1 and the HHV-8-negative cell line BJAB were stimulated with TPA for 24 or 65 h, an early and late time point in HHV-8 viral replication, respectively. As TPA induced a rapid NF-kB activation after 1 h that was unrelated to viral replication events, this time point was not included in the experiment. The immunoprecipitated IKK complex was tested for kinase activity using GST-IkBa (aa 1-55) substrate as well as the mutated IkBa substrate with Ser32/36Ala substitutions. An increase in IKK kinase activity was easily detectable at 65 h in BCBL-1 cells (Figure 2a The results of the in vitro kinase assay were extended by measuring endogenous IkBa phosphorylation and NF-kB DNA binding under the same conditions used for the kinase assay. Whole-cell extracts from TPAstimulated BCBL-1 and BJAB cells were analysed using a phosphospecific antibody against the Ser32/Ser36 phosphorylated IkBa, which detected the phosphorylated form of IkBa in both BJAB and BCBL-1 at 1 h after TPA treatment (Figure 3a, lanes 4 and 8) ; however, only BCBL-1 cells exhibited phosphorylated IkBa at 65 h (Figure 3a , lane 10). These results correlate with EMSA analysis of NF-kB binding to the PRDII probe (Figure 3b ), demonstrating an NF-kB p65/p50 complex only in BCBL-1 cells at 1 and 65 h of TPA treatment (Figure 3b , lanes 8 and 10; Figure 3c , lanes 2, 3, 7 and 8).
Together, these results indicate that the activation of NF-kB during the HHV-8 lytic cycle requires the production of viral lytic proteins and the activation of the IKK complex, which leads to the nuclear binding of p65/p50 heterodimers.
Generation of BCBL-1 cells expressing the IkBa 2ND4 super-repressor
To investigate the role of NF-kB induction during HHV-8 lytic replication, BCBL-1 cells were engineered to express the super-repressor IkBa 2ND4 (Kwon et al., Figure 2 Induction of IKK complex kinase activity during the HHV-8 lytic cycle. (a) BCBL-1 cells were treated with TPA (20 ng/ ml) for 0, 24 and 65 h to induce HHV-8 lytic replication and assayed for IKK kinase activity (lanes 6-8). TPA-treated BJAB cells were used as a negative control for nonspecific IKK activation (lanes 3-5) and U937 cells stimulated with TNF-a for 20 min were used as positive controls (lanes 1 and 2). Top section: The IKK kinase complex was immunoprecipitated from whole-cell extracts (500 mg) with an anti-IKKg antibody and used in an in vitro kinase assay with GST-IkBa (1-55 aa) as substrate. Immunoblot against IKKb shows that equivalent amounts of kinase were immunoprecipitated for each point. Coomasie Blue staining of the substrate peptide shows equal amounts in each sample. Bottom section: As above but using a mutant substrate GST-IkBa S32/36A to demonstrate specificity of the IKK kinase activity. (b) Whole-cell extracts (100 mg) from (a) were analysed for HHV-8 lytic protein production by immunoblot using antisera against the products of ORF 26 and ORF K8.1 NF-jB activity and HHV-8 infectivity M Sgarbanti et al 1998) using the pMSCVneo retrovector. IkBa 2ND4 is a mutated form of IkBa containing the Ser32/36Ala mutation (2N) as well as a C-terminal 22-aa deletion (D4) in the PEST domain, a region involved in the constitutive turnover of this protein Lin et al., 1996) . Stable ectopic expression of IkBa 2ND4 in BCBL-1 resulted in the inhibition of HHV-8-induced NF-kB binding ( Figure 4a , lane 4) and also in the complete inhibition of the expression of the endogenous IkBa protein ( Figure 4b , lane 2), in agreement with the fact that IkBa is an NF-kB-regulated gene (Le Bail et al., 1993; Sun, 1993) .
Similar HHV-8 virus yields from TPA-stimulated BCBL-1 and BCBL-1 2ND4 cells
To determine if NF-kB inhibition via IkBa2ND4 expression affected the ability of HHV-8 to reactivate from latency, BCBL-1 and 2ND4 cells were stimulated with TPA for 2, 4 and 6 days, and virus expression was estimated by immunoblotting for the lytic K8.1 glycoprotein ( Figure 5a ). A progressive accumulation of K8.1 occurred from days 2 to 6 after TPA treatment, clearly showing that expression of 2ND4 did not affect the capacity of HHV-8 to switch from latent to lytic phase ( Figure 5a , lanes 2-4 for BCBL-1, lanes 6-8 for BCBL-1 Neo and lanes 10-12 for 2ND4). Moreover, 2ND4 cells appear to produce more K8.1 protein than the control cells, an unexpected result that awaits further examination. The ability of 2ND4 cells to produce viral particles was next investigated by treating BCBL-1 and 2ND4 cells for 24 h with the combination of TPA and Ionomycin (TPA/Iono). Similar amounts of virus were released from BCBL-1, Neo and 2ND4 cells, as detected by Southern blot analysis of viral DNA released on day 5 after induction, using a specific probe for HHV-8 ORF 75 (Figure 5b lanes 2-4) . Although in Figure 5b , supernatants from 2ND4 cells seem to have somewhat less ORF 75, this difference was neither significant nor reproducible in subsequent experiments. Based on this analysis, the estimated virus titer was approximately 4.6 Â 10 7 virions/ml from each of the cell lines.
HHV-8 from BCBL-1 2ND4 is incapable of initiating de novo infection
The infectivity of HHV-8 virions derived from BCBL-1 and BCBL-1-2ND4 cells was determined in a de novo infection assay (schematically represented in Figure 6a ): HHV-8 virus was collected 5 days after TPA/Iono treatment, concentrated by ultracentrifugation and used to infect the endothelial hybrid cell line Ea-hy926 (Edgell et al., 1983; Antoine et al., 1994; Lagunoff, 2002) . Infectivity was monitored at 72 h by measuring K8.1 glycoprotein and ORF 26 minor capsid protein expression in Ea-hy926 cells by immunoblotting (Figure 6b ) or by semiquantitative PCR using specific primers to amplify ORF 75 (Nicholas et al., 1997) The capacity of HHV-8 virions from BCBL-1 and 2ND4 cells to enter EA.hy926 cells was next tested using GFPcontaining virus preparations (Webb et al., 1999; Gurer et al., 2002) . To this end, BCBL-1 cells were transduced with a retrovector encoding GFP (Figure 7a ) and then stimulated with TPA to induce HHV-8 lytic replica tion. We postulated that HHV-8, being a large enveloped virus, would be able to shuttle cytoplasmic (Figure 7b ). This result demonstrates that cytoplasmic GFP was efficiently shuttled by HHV-8 virions into the target cells during de novo infection. The similar percentage of GFPpositive Ea.hy926 cells after infection indicates that the defect in infectivity of HHV-8 virus from 2ND4 cells was not due to a block in virus entry.
A possible explanation for the attenuation of HHV-8 derived from 2ND4 cells is that expression of viral genes required for efficient de novo infection are dependent on NF-kB activity. To examine this possibility, BCBL-1 and 2ND4 cells were stimulated with TPA/Iono and analysed for viral mRNA expression by semiquantitative RT-PCR with specific primers for over 50 HHV-8 ORFs (Jenner et al., 2001) . The mRNA expression of ORF19 and ORF20 was reduced three-to fourfold in 2ND4 cells (Figure 8 lanes 2 and 4) , whereas the profiles of other ORFs (including ORF 17, ORF 12, ORF 74, ORF K2 and ORF 50) demonstrate that their mRNAs were expressed at equivalent levels in both cell types. Other experiments, however, argue against the involvement of ORF 19 and ORF 20 in the regulation of HHV-8 infectivity (data not shown), and thus implicate a cellular process that may be required for HHV-8 de novo infection. Discussion PEL (also called body cavity-based lymphoma, BCBL) is a rare non-Hodgkin's lymphoma of B-cell origin associated with HHV-8 infection (Chang et al., 1994; Cesarman et al., 1995) that occurs predominantly in immunocompromised individuals, such as AIDS patients (Drexler et al., 1998) . Although the exact maturation stage of PEL cells remains controversial (Matolcsy et al., 1998; Carbone et al., 2000) , the lymphoma is thought to arise from B cells of a mature, postgerminal center, preterminal differentiation stage Figure 6 De novo HHV-8 infection of endothelial Ea.hy926 cells. (a) Schematic representation of the de novo infection protocol. WT, Neo and 2ND4 cells were stimulated with TPA (20 ng/ml) and Ionomycin (500 ng/ml) for 24 h to induce the HHV-8 lytic cycle and supernatants collected 65 h postinduction. After ultracentrifugation, the virus was used to de novo infect Ea.hy926 cells. The virus titer was estimated by Southern blotting to be 7.6 Â 10 8 virions/ml, with an MOI of 5400. (b). Whole-cell extracts (70 mg) extracted from Ea.hy926 cells at 72 h postinfection with HHV-8 derived from WT (lanes 1 and 2), Neo (lanes 3 and 4) and 2ND4 (lanes 5 and 6) cells were analysed by immunoblot using antibodies against ORF 26 and ORF K8.1 products. Lanes 2, 4 and 6 show viral protein levels after de novo infection. Lanes 1, 3 and 5 show viral protein levels when the viral preparations are treated by 60 s of UV crosslinking. (c) PCR amplification of ORF 75 from Ea.hy926 genomic DNA collected 72 h postinfection. Amplification of actin DNA was used as a control. (d) Whole-cell extracts from panel b were used to perform EMSA using the PRDII probe (lanes 1-6). Supershift analysis with specific antibodies against p65, p50 and c-Rel are shown in lanes 7-14, as indicated NF-jB activity and HHV-8 infectivity M Sgarbanti et al Gaidano et al., 1997) . Cells isolated from PEL lesions harbor clonal rearrangement of the immunoglobulin genes, but do not express surface B-cell receptor and lack most B-cell-associated surface antigens such as CD20, CD22 and CD19 (Drexler et al., 1998) . In recent studies, we demonstrated dramatic alterations in the B-cell transcriptional program that may contribute to lymphomagenesis and the development of the non-B, non-T phenotype in PEL cells (Arguello et al., 2003) .
The IKK-NF-kB signaling pathway is a frequent target of virus manipulation during infection (for a review see Hiscott et al., 2001) . Although the activation of NF-kB by viral infection may serve to activate the immune response to invading pathogens, several viruses have developed strategies to harness this pathway to drive viral gene expression and replication, as well as to prevent cell death. In this regard, HHV-8 activates the NF-kB pathway through the expression of vFLIP, which binds to and persistently activates the IKK and BCBL-1 2ND4-GFP cells were induced with TPA (20 ng/ml) and Ionomycin (500 ng/ml) for 24 h and the supernatants containing HHV-8 virions were collected at 65 h, concentrated by ultracentrifugation and used to infect Ea-hy926 cells. Infection was performed in the serum-free media for 7.5 h; cells were harvested by trypsinization and the number of GFP-positive cells was determined by FACS analysis. Uninfected Ea-hy926 cells were used as a negative control complex (Liu et al., 2002) . This interaction results in the induction of a survival pathway that effectively inhibits caspase-mediated apoptosis via engagement of the Fas receptor. Overexpression of the early lytic protein vGPCR (Bais et al., 1998; Yang et al., 2000; Guo et al., 2003) has also been shown to induce NF-kB (Montaner et al., 2001; Pati et al., 2001; Schwarz and Murphy, 2001; Chiou et al., 2002; Smit et al., 2002) through the activation of PI3-K/AKT and IKK pathways (Montaner et al., 2001; Pati et al., 2001) .
The objective of the present study was to investigate the involvement of NF-kB activation in HHV-8 lytic replication and de novo infection. Activation of HHV-8 replication in the PEL cell line BCBL-1 following TPA treatment resulted in two peaks of NF-kB activation. The initial peak occurred early after TPA treatment, corresponding to TPA-induced NF-kB DNA-binding activity. A second peak of NF-kB activity was also observed at 65 h corresponding to HHV-8 lytic replication in BCBL-1 cells. Utilization of the inhibitor MTX did not block TPA-induced NF-kB activity, but blocked the second peak of virus-induced NF-kB activation that is mediated through increased IKKb kinase activity. In BCBL-1 cells expressing the IkBa 2ND4 super-repressor, HHV-8-induced NF-kB activation was completely abolished. As reported previously (Keller et al., 2000) , NF-kB blockade in PEL cells causes apoptosis as a consequence of the inhibition of hIL-6 production, a growth factor for PEL (Asou et al., 1998) . In the present study, no difference in the growth rate of BCBL-1 2ND4 cells and BCBL-1 cells was observed. A possible explanation for this apparent discrepancy may be that BCBL-1 and 2ND4 cells express high levels of vIL-6 (ORF K2) even in the absence of TPA/Iono stimulation, and thus vIL-6 may serve as an autocrine growth factor for BCBL-1 (Jones et al., 1999) .
Following TPA/Iono induction of BCBL-1 or 2ND4 cells, HHV-8 appears to be fully capable of reactivation from latency with similar virus yields, based on the evaluation of viral DNA extracted from HHV-8 virions. The capacity of virus recovered from the BCBL-1 2ND4 cells to initiate an efficient de novo infection of the endothelial cell line Ea.hy926 was then examined. The reports of successful HHV-8 de novo infection of cultured endothelial cells have been few and controversial to date (Flore et al., 1998; Moses et al., 1999; Ciufo et al., 2001; Sakurada et al., 2001) . Recently, however, de novo infection and serial transmission of HHV-8 was obtained using telomerase-immortalized microvascular endothelial cells and a concentrated virus stock preparation (Lagunoff, 2002) . Using the same approach, Ea.hy926 cells (originally derived by fusion of human umbilical vein endothelial cells and the human carcinoma cell line A549) (Edgell et al., 1983; Antoine et al., 1994) were infected with the rescued, concentrated virus; clearly, HHV-8 was recovered from the 2ND4 cells but not the BCBL-1 parental cells, which were impaired for de novo infection of Ea.hy926 cells. Thus, NF-kB activity appears to be required for the HHV-8 lytic cycle and may act to facilitate postentry replicative steps or virion maturation. The fact that high levels of lytic proteins ORF K8.1 and ORF 26 were detected after HHV-8 infection also indicates that Ea.hy926 cells may be a convenient model to examine de novo HHV-8 replication in the absence of pharmacological induction. While the viral and/or host events that are sensitive to NF-kB inhibition remain to be elucidated, the present studies demonstrate that NF-kB activation, via the classical IKKa/IKKb kinase complex, is required for the regulation of aspects of HHV-8 infectivity. The BCBL-1 2ND4 cell model has proven useful in the analysis of NF-kB function in the context of virus infection and will be important in future studies to further characterize the role of NF-kB in HHV-8-induced lymphomagenesis.
Our results are apparently at odds with a recent study of Brown et al. (2003) , who in their reporter gene model demonstrated that overexpression of p65 represses the transactivation potential of ORF 50, a protein involved in the switch to lytic replication. They argue that high levels of NF-kB may activate a cellular protein that participates in the repression of gammaherpesvirusspecific gene expression, therefore inhibiting lytic replication. These authors suggest that constitutively high NF-kB activity may therefore contribute to the establishment and maintenance of viral latency in lymphocytes. While compelling, this hypothesis is 4) and total RNA extracted at 65 h was analysed by semiquantitative RT-PCR using specific primers to amplify HHV-8 ORF 17, ORF 19, ORF 20, ORF K12, ORF 74, ORF K2, ORF 50. Total RNA was also extracted from unstimulated BJAB cells and used for RT-PCR as a negative control for HHV-8-specific gene expression (lane 5). Right-hand panel: BCBL-1 cells were stimulated with TNF-a to induce NF-kB activity and analysed for HHV-8 gene expression at different time points by RT-PCR as described previously. Specific primers to amplify GAPDH were used as a control for equal amount of cDNA used in PCR amplification NF-jB activity and HHV-8 infectivity M Sgarbanti et al contradictory to the fact the HHV-8 encodes at least two pirated genes -vGPCR and vFLIP -that are capable of activating NF-kB. vGPCR, in particular, activates the NF-kB pathway early during the lytic cycle in PEL cells through the PI3K-AKT axis (Cannon et al., 2003) . It would be surprising if this activation was detrimental to virus replication since it contributes to the production of VEGF and IL6, two important growth factors in HHV-8-associated diseases.
Materials and methods
Cell culture
BJAB and BCBL-1 cells (a generous gift from Dr Jae Jung) were grown in RPMI1640 supplemented with 10%, heatinactivated, fetal bovine serum. The transduced BCBL-1(Neo), BCBL-1(2ND4), BCBL-1(Neo)-GFP, BCBL-1(Neo)-2ND4-GFP cells were grown in RPMI1640 supplemented with 10%, heat-inactivated, fetal bovine serum and 500 mg/ml of G418 (GIBCO). Ea.hy926 cells (a generous gift from Dr CoraJean S Edgell) as well as the amphotropic Phoenix packaging cell line (obtained from ATCC with permission from Dr Gary Nolan) were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10%, heat-inactivated, fetal bovine serum. U937 cells were grown in RPMI1640 supplemented with 5% Fetalclone I. For TPA stimulation of BCBL-1, cells were plated at 10 5 cells/ml 24 h prior to stimulation with 20 ng/ml of TPA (Sigma) with or without 500 ng/ml of Ionomycin (Biomol) for 24 h. Where indicated, cells were treated with MTX at a final concentration of 1 mM or with TNF-a (10 ng/ml) for the indicated time points.
Retrovector construction, transduction and generation of BCBL-1 cells
The pMSCVneo IkB-a 2ND4 retrovector was generated by amplifying the sequence encoding IkB-a 2ND4 from the CMVt-IkB 2ND4 plasmid (Kwon et al., 1998) by PCR (981C 45 s, 481C 45 s, 721C 2 min, for 20 cycles) using Pfu DNA polymerase (Stratagene) with the following primers: 5 0 -CCGGAATTCGTCGCCACCATGTTCCAGGCGGCCG AGCG-3 0 and 5 0 -GGAAGATCTTTAGAACTCTGACTCT GTG-3 0 . The cloning product was verified by sequencing, cleaved with EcoRI and BglII (EcoRI and BglII restriction sites were inserted within the primers) and cloned into pMSCVneo retrovector (Clontech), cut with the same enzymes. The pMSCVpuro CMV-GFP retrovector was generated by blunt end cloning of the 1450 bp fragment obtained by the digestion of the pEGFP-C1 plasmid (Clontech) with AseI and DraI restriction enzymes into the pMSCVpuro retrovector (Clontech) digested with HpaI; sense and antisense orientations of the inserted fragment were verified by EcoRI digestion. The Phoenix Amphotropic packaging cell line was transiently transfected as described (www.stanford.edu/groupnolan/phxhelper.html) with the plasmids pMSCVneo, pMSCVneo IkBa 2ND4 and pMSCVpuro CMV-GFP. At 24 h post-transfection, DMEM was replaced with RPMI1640 and 24 h later, retrovirus containing medium was harvested and used to infect BCBL-1 (pMSCVneo and pMSCVneo IkBa 2ND4) or BCBL-1(Neo) and BCBL-1 (2ND4) cells (pMSCVpuro CMV-GFP). BCBL-1 cell lines were infected twice at 24 h intervals in the presence of 10 mg/ml of polybrene (Sigma); selection with 500 mg/ml of G418 (GIBCO) was started 5 days later. After 14 days, a population of resistant BCBL-1 cells was selected. For BCBL-1 (Neo) and BCBL-1 (2ND4) transduced with pMSCVpuro CMV-GFP cells were selected for GFP expression by FACS cell sorting at day 10 after transduction.
Immunoblot analysis
Equivalent amounts of whole-cell (whole-cell extract lysis buffer: 50 mM Tris/HCl pH 7.4, 1 mM EDTA, 150 mM NaCl, 20 mM b-glycerophosphate, 5 mM NaF, 10% glycerol, 1% NP-40, 1 mM orthovanadate, 1 mM PMSF, 5 mg/ml of aprotin and 5 mg/ml of leupeptin) and nuclear extracts (described in Kwon et al., 1998 with modifications: buffers A, 10 mM HEPES, pH 7.5, 50 mM NaCl, 10 mM EDTA pH 8, 5 mM MgCl 2 ; and B, 10 mM HEPES, pH 7.5, 400 mM NaCl, 1 mM EDTA pH 8, 5 mM MgCl 2 , both complemented with: 20 mM b-glycerophosphate, 1 mM orthovanadate, 1 mM PMSF, 50 mM NaF, 5 mg/ml of aprotin and leupeptin and 1 mM DTT) from the different cell lines were subjected to 12% sodium dodecylsulfate-polyacrylamide gel (SDS-PAGE). After electrophoresis, proteins were transferred to a nitrocellulose membrane TransBlot (Bio-Rad) in a buffer with 30 mM Tris, 200 mM glycine and 20% methanol for 1 h and 15 min at 250 mA at 41C. The membrane was blocked in 5% dried skim milk in phosphateor tris-buffered saline (PBS or TBS) plus 0.05% Tween-20 overnight at 41C, and then was probed with specific antibodies recognizing HHV-8 minor capsid protein ORF-26 (Fitzgerald Industries, Inc.), HHV-8 ORF K8.1 (Advanced Biotechnology Inc.), IKK-b 10AG2 (Alexis Biochemical, Inc.), IkBa MAD10B as described (Kwon et al., 1998) , phosphospecific IkBa Ser32/36 (Cell Signaling, Inc.), b-actin (Sigma) and TFIID (Santa Cruz).
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts (5 mg) obtained as described above were diluted with buffer C: 10 mM HEPES, pH 7.5, 1 mM EDTA pH 8, 5 mM MgCl 2 , complemented with: 20 mM b-glycerophosphate, 1 mM orthovanadate, 1 mM PMSF, 50 mM NaF, 5 mg/ ml of aprotin and leupeptin and 1 mM DTT, and subjected to EMSA, by using a double-stranded, 32 P-labeled, oligonucleotide corresponding to two copies of the PRDII region of the IFN-b promoter: 5 0 -GGGAAATTCCGGGAAATTCC-3 0 . The protein-DNA binding reaction was performed in 10 mM HEPES pH 7.9, 40 mM KCl, 0.2 mM MgCl 2 , DTT 1 mM, PMSF 0.05 mM, EDTA 1 mM, NP-40 0.2%, glycerol 2%, BSA 1 mg/ml, 1 mg/ml of poly(dI-dC) and the reaction mixture was loaded on a nondenaturing 5% PAGE (60 : 1 crosslink) in 0.25 Â Tris-borate-EDTA (TBE), using an EMSA loading buffer: 50 mM HEPES pH 7.9, Ficoll 400 20%. After 3 h at 150 V, the gel was dried and exposed to film for 16 h at À701C. Supershift analysis was performed by incubating the reaction mixture with 1 ml of specific antibodies (Santa Cruz) for NF-kB subunits p50 , p65 (C-20), c-Rel (N), Rel-B (C-19) and p52 (C-5).
Immunoprecipitation and in vitro kinase analysis of IKK Whole-cell extracts (500 mg) from U937, BJAB and BCBL-1 cells were used to immunoprecipitate the IKK kinase complex using a specific IKK-g (FL-419) antibody (Santa Cruz). Immunoprecipitation was performed for 4 h at 41C, after an initial 2 h precoupling at 41C of 2 mg of the antibody with 30 ml of packed protein A-sepharose in 600 ml of 50 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.1% NP-40 and 1% BSA. Protein A-sepharose beads with the bound proteins were washed twice with whole-cell extract lysis buffer and twice with kinase buffer (10 mM HEPES pH 7.4, 5 mM MgCl 2 , 50mM orthovanadate, 10 mM b-glycerophosphate, 1 mM DTT, 50 mM NaCl, 10 mM PNPP). In vitro kinase assay was performed by adding to the dried beads GST-purified GST-IkB-a (1-55) or GST-IkB-a (1-55, Ser32/36Ala) substrate (1 mg) Ishii et al., 2001) , 10 mM cold ATP and 10 mCi of [g-32 P]ATP in kinase buffer. The kinase reaction was performed at 301C for 30 min and stopped by the addition of 4 Â SDS sample buffer. The samples were analysed by 10% SDS-PAGE and the dried gels were exposed to film at À701C for 5 h.
Hhv-8 de novo infection
BCBL-1 WT, Neo and 2ND4 cells, plated at 3 Â 10 5 /ml 24 h prior to treatment were induced to undergo lytic replication by treatment with TPA (20 ng/ml) and ionomycin (500 ng/ml) for 24 h. HHV-8 containing supernatant from each cell line was collected at day 5, filtered through a Millex-HV 0.45 filter and viral particles were concentrated by ultracentrifugation as described (Lagunoff, 2002) ; concentrated virus was used for de novo infection of EA.hy926 cells. Where indicated, UV inactivation of HHV-8 was performed using the Stratagene Stratalinker; supernatant from BCBL-1 was exposed for 2 Â 30 s cycles of auto-crosslinking irradia tion (1200 mJ Â 100 for each cycle) prior to application to Ea.hy926 cells. De novo infection was performed as described (Lagunoff, 2002) with modifications: Ea.hy926 cells were infected for 2 h in the serum-free media, then serum was added without changing the media and cells were collected at 72 h. Ea.hy926 cells were infected using 7.6 Â 10 8 virions/ml, back calculated by Southern blotting (Lagunoff, 2002) (estimated multiplicity of infection (MOI) 5400). The level of HHV-8 DNA in Ea.hy926-infected cells was also measured by PCR amplification of ORF 75 from genomic DNA as described (Nicholas et al., 1997) ; b-actin was PCR amplified as a control for equal amounts of genomic DNA in the PCR reactions (b-actin primers: 5 0 -GATGGGCACAGTG TGGGTGA-3 0 ; 5 0 -ACAATGAGCTGCTGGTGGCT-3 0 ). The de novo infection using HHV-8 from BCBL-1(Neo)-GFP or BCBL-1 2ND4 GFP was performed for 7 h in the serum-free media; cells were washed twice in PBS and collected by 0.25% trypsin treatment; cells were resuspended in PBS and the number of GFP-positive de novo infected cells was determined by FACS.
Southern blot analysis of viral DNA
To estimate the amount of HHV-8 in each virus stock, an aliquot of the concentrated virus was treated with DNase 1, and viral DNA was extracted from virions, BamHI digested and subjected to Southern blotting analysis as described (Renne, 1996) . A specific 0.5 kb BamHI DNA fragment from the ORF 75 region of HHV-8 was PCR amplified using the primers 5 0 -CTAGAGATCTGTTTAGTCCGGAG-3 0 and 5 0 -GTACGGATCCACGGAGCAT-3 0 (Nicholas et al., 1997) , end labeled with [g-32 P]ATP by T4 polynucleotide kinase and used as probe in Southern blot analysis. Virus titer was estimated by comparing the intensity of Southern blot hybridization of HHV-8 DNA to known serial dilutions of the ORF 75 probe.
RT-PCR analysis
Total RNA was extracted from 20 Â 10 6 cells by TRIZOL (Invitrogen) and cDNA was obtained by reverse transcription of total RNA (1 mg) using the Advantage for RT-for-PCR-Kit (Clontech). cDNA was then diluted 1 : 50 and used to perform semiquantitative PCR (with titration of the cycles to keep the amplification in a linear range) using all the specific HHV-8 primers listed at www.biochem.ucl.ac.uk./bsm/virus_database/ KSHVarray.html. (Jenner et al., 2001) . PCR amplifications were performed for 1 min at 981C, 1 min at 581C, for 2 min at 721C for the following cycles: 20 for ORF 17, 23 for ORF19 and ORF 20, 25 for ORF 50, 25 for ORF 74, 20 for ORFK 2, 20 for ORFK 12, 15 for GAPDH. GAPDH primers were provided with RT-for-PCR-Kit (Clontech). Quantification of the PCR fragments amplified by PCR was obtained using ImageQuant software after scanning the DNA gel in a Typhoon 9400 PhosphoImager (Amersham Pharmacia).
